Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

lifitegrast MeSH Supplementary Concept Data 2026


MeSH Supplementary
lifitegrast
Unique ID
C575157
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C575157
Entry Term(s)
(2S)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid
L-phenylalanine, n-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)-
SAR 1118
SAR-1118
SHP-606
SHP606
Xiidra
lifitegrast ophthalmic solution
Pharm Action
Ophthalmic Solutions
Registry Numbers
038E5L962W
Heading Mapped to
Phenylalanine / analogs & derivatives
*Sulfones
Frequency
38
Note
An LFA-1 (LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1) antagonist that is used in the treatment of DRY EYE SYNDROMES.
Source
J Ocul Pharmacol Ther. 2011 Feb;27(1):99-104.
Indexing Information
Lymphocyte Function-Associated Antigen-1
Date Introduced
2012/09/25
Last Updated
2019/10/30
lifitegrast Preferred
SAR 1118 Narrower
Xiidra Narrower
SHP-606 Narrower
lifitegrast ophthalmic solution Related
page delivered in 0.004s